William Blair Reiterates Biohaven Pharmaceutical (BHVN) at Outperform, Nurtec ODT Will Eventually Become Blockbuster Franchise

William Blair analyst Tim Lugo reiterated an Outperform rating on Biohaven Pharmaceutical Holding (NYSE: BHVN), following the company's most recent quarterly report.

The analyst quotes: "We view Nurtec ODT as the leader in acute migraine and believe the approval for the preventive treatment of episodic migraine in mid-2021 will solidify the product’s position as the leading innovative therapy for migraine. With Nurtec ODT already commanding a significant market share in the acute setting, we believe the simplicity of a single treatment, combined with the head start over competitor AbbVie’s Qulipta, further reinforces the long runway of top-line growth ahead and believe the product will eventually become a blockbuster franchise for Biohaven. We also believe the company has a deep and underappreciated pipeline of assets across a range of neurology indications that could offer significant upside for the company, including expansion of its CGRP platform across both migraine and nonmigraine indications, troriluzole in OCD and SCA, and verdiperstat in ALS. We maintain our Outperform rating."

For an analyst ratings summary and ratings history on Biohaven Pharmaceutical Holding click here. For more ratings news on Biohaven Pharmaceutical Holding click here.

Shares of Biohaven Pharmaceutical Holding closed at $133.81 yesterday.

By Vlad Schepkov | [email protected]

You May Also Be Interested In

• Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'